Industry Strength Score
11/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ZOMEDICA CORP (ZOM) Stock Price & Overview
NYSEARCA:ZOM • CA98980M1095
Current stock price
0.0973 USD
0 (-0.21%)
Last:
The current stock price of ZOM is 0.0973 USD. Today ZOM is down by -0.21%. In the past month the price decreased by -19.59%. In the past year, price decreased by -30.94%.
ZOM Key Statistics
52-Week Range0.092 - 0.1952
Current ZOM stock price positioned within its 52-week range.
1-Month Range0.092 - 0.1229
Current ZOM stock price positioned within its 1-month range.
- Market Cap
- 95.349M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.03
- Dividend Yield
- N/A
ZOM Stock Performance
Today
-0.21%
1 Week
-12.18%
1 Month
-19.59%
3 Months
-22.72%
Longer-term
6 Months -23.27%
1 Year -30.94%
2 Years -54.04%
3 Years -71.13%
5 Years -48.71%
10 Years N/A
ZOM Stock Chart
ZOM Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ZOM. When comparing the yearly performance of all stocks, ZOM is a bad performer in the overall market: 85.19% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ZOM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZOM. No worries on liquidiy or solvency for ZOM as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ZOM Earnings
On March 13, 2025 ZOM reported an EPS of -0.01 and a revenue of 7.00M. The company missed EPS expectations and missed revenue expectations (-20.3% surprise).
Next Earnings DateMay 7, 2025
Last Earnings DateMar 13, 2025
PeriodQ3 / 2024
EPS Reported-$0.01
Revenue Reported7M
EPS Surprise %
Revenue Surprise -20.30%
ZOM Forecast & Estimates
5 analysts have analysed ZOM and the average price target is 0.26 USD. This implies a price increase of 162.08% is expected in the next year compared to the current price of 0.0973.
For the next year, analysts expect an EPS growth of -110.78% and a revenue growth 10.67% for ZOM
Analysts
Analysts80
Price Target0.26 (167.21%)
EPS Next Y-110.78%
Revenue Next Year10.67%
ZOM Financial Highlights
Over the last trailing twelve months ZOM reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -57.89% compared to the year before.
Income Statements
Revenue(TTM)26.73M
Net Income(TTM)-62.19M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.05% | ||
| ROE | -30.66% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-900%
Sales Q2Q%10.29%
EPS 1Y (TTM)-57.89%
Revenue 1Y (TTM)11.33%
ZOM Ownership
Ownership
Inst Owners9.39%
Shares979.95M
Float961.51M
Ins Owners0.74%
Short Float %N/A
Short RatioN/A
ZOM Industry Overview
ZOM operates in the Health Care Equipment sub-industry within the Health Care sector. This group contains 127 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
59/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
22%
Outperformed 22% of sub-industries
3 Month Rank
14%
Outperformed 14% of sub-industries
6 Month Rank
11%
Outperformed 11% of sub-industries
Industry Fundamentals & Breadth
- Members
- 127
- New Highs
- 2.4%
- New Lows
- 14.2%
- Average ROE
- 17.2%
- Average Profit Margin
- 20.3%
- Average Operating Margin
- 22.5%
- Average P/E
- 28.3
- Average Fwd P/E
- 27.4
- Average Debt/Equity
- 0.5
ZOM Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 39.25 | 162.59B | ||
| ABT | ABBOTT LABORATORIES | 14.24 | 155.452B | ||
| SYK | STRYKER CORP | 17.41 | 112.876B | ||
| BSX | BOSTON SCIENTIFIC CORP | 14.31 | 83.969B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.9 | 48.418B | ||
| IDXX | IDEXX LABORATORIES INC | 38.32 | 45.068B | ||
| BDX | BECTON DICKINSON AND CO | 10.94 | 42.515B | ||
| RMD | RESMED INC | 16.7 | 29.867B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 10.74 | 27.847B | ||
| DXCM | DEXCOM INC | 20.18 | 23.611B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 9.11 | 16.047B | ||
| PEN | PENUMBRA INC | 63.83 | 12.792B | ||
| GMED | GLOBUS MEDICAL INC - A | 20.03 | 12.354B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ZOM
Company Profile
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 144 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.
Company Info
IPO: 2013-10-28
ZOMEDICA CORP
100 Phoenix Drive, Suite 125
Ann Arbor MICHIGAN 48108 US
CEO: Robert Cohen
Employees: 144
Phone: 17343692555
ZOMEDICA CORP / ZOM FAQ
Can you describe the business of ZOMEDICA CORP?
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 144 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.
Can you provide the latest stock price for ZOMEDICA CORP?
The current stock price of ZOM is 0.0973 USD. The price decreased by -0.21% in the last trading session.
What is the dividend status of ZOMEDICA CORP?
ZOM does not pay a dividend.
What is the ChartMill technical and fundamental rating of ZOM stock?
ZOM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists ZOM stock?
ZOM stock is listed on the NYSE Arca exchange.
What do analysts say about ZOMEDICA CORP (ZOM) stock?
5 analysts have analysed ZOM and the average price target is 0.26 USD. This implies a price increase of 162.08% is expected in the next year compared to the current price of 0.0973.
When does ZOMEDICA CORP (ZOM) report earnings?
ZOMEDICA CORP (ZOM) will report earnings on 2025-05-07.